Holen Sie sich die Stockscreener-App
1.17
1.68%
-0.02
Handel nachbörslich:
1.13
-0.04
-3.42%
Schlusskurs vom Vortag:
$1.19
Offen:
$1.23
24-Stunden-Volumen:
57,836
Relative Volume:
1.17
Marktkapitalisierung:
$14.00M
Einnahmen:
$996.00K
Nettoeinkommen (Verlust:
$-6.09M
KGV:
-2.2075
EPS:
-0.53
Netto-Cashflow:
$-9.76M
1W Leistung:
+8.33%
1M Leistung:
-19.31%
6M Leistung:
+7.34%
1J Leistung:
-31.98%
1-Tages-Spanne:
$1.11
$1.23
1-Wochen-Bereich:
$1.08
$1.23
52-Wochen-Spanne:
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Vergleichen Sie TXMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.17 | 14.00M | 996.00K | -6.09M | -9.76M | -0.53 |
|
RGC
Regencell Bioscience Holdings Ltd
|
20.19 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.79 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.42 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.56 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
| 2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Eingeleitet | Guggenheim | Buy |
| 2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
| 2018-06-15 | Eingeleitet | JP Morgan | Overweight |
| 2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-07 | Fortgesetzt | Guggenheim | Buy |
| 2016-04-04 | Eingeleitet | Goldman | Buy |
| 2015-12-08 | Bestätigt | Jefferies | Buy |
| 2015-12-08 | Bestätigt | Stifel | Buy |
| 2015-09-21 | Bestätigt | Jefferies | Buy |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2014-07-08 | Eingeleitet | FBR Capital | Outperform |
| 2014-04-17 | Bestätigt | Noble Financial | Buy |
| 2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
Mayne Pharma Group Unit Seeks Over $11.5 Million in Damages in US Court Complaint Against TherapeuticsMD - marketscreener.com
Mayne Pharma Files Legal Complaint Against TherapeuticsMD - TipRanks
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com - Defense World
TherapeuticsMD Reports Improved Q1 2025 Results - TipRanks
TherapeuticsMD Announces First Quarter 2025 Financial Results | - GuruFocus
TherapeuticsMD: Q1 Earnings Snapshot - CT Insider
TherapeuticsMD Announces First Quarter 2025 Financial Results - BioSpace
TherapeuticsMD Inc Reports Q1 2025 Results: EPS at -$0.06, Revenue Reaches $393K - GuruFocus
TherapeuticsMD Reports Q1 2025 Financial Results - TipRanks
TherapeuticsMD Q1 Operating Expenses USD 1.264 Million - marketscreener.com
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD) - TheStreet
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Press Release Distribution & PR Platform - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock By Investing.com - Investing.com Canada
TherapeuticsMD director Tommy Thompson acquires $325 in stock - Investing.com Australia
TherapeuticsMD director Tommy Thompson acquires $325 in stock By Investing.com - Investing.com Canada
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock - Investing.com
TherapeuticsMD CEO Marlan Walker buys $489 in common stock By Investing.com - Investing.com South Africa
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Mayne Pharma Faces Legal Challenge from TherapeuticsMD - TipRanks
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock - Investing.com Australia
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock By Investing.com - Investing.com India
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsmdFiles Lawsuit Against Mayne Pharma For Breach Of Contract - MarketScreener
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Therapeuticsmd Inc-Aktie (TXMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Walker Marlan D | Chief Executive Officer |
Apr 14 '25 |
Buy |
1.00 |
490 |
489 |
73,639 |
| Walker Marlan D | Chief Executive Officer |
Apr 10 '25 |
Buy |
0.86 |
1,167 |
1,000 |
73,149 |
| Walker Marlan D | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.87 |
1,136 |
994 |
71,982 |
| Collins Cooper C. | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
60,516 |
| Naughton Gail K | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
8,500 |
| Thompson Tommy G | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
14,454 |
| Walker Marlan D | Chief Executive Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
8,281 |
0 |
70,846 |
| Collins Cooper C. | Director |
Aug 22 '24 |
Buy |
1.73 |
4,094 |
7,099 |
52,016 |
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
3.92%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):